CN107184584B - 一种治疗阿尔茨海默病的药物 - Google Patents
一种治疗阿尔茨海默病的药物 Download PDFInfo
- Publication number
- CN107184584B CN107184584B CN201710444718.3A CN201710444718A CN107184584B CN 107184584 B CN107184584 B CN 107184584B CN 201710444718 A CN201710444718 A CN 201710444718A CN 107184584 B CN107184584 B CN 107184584B
- Authority
- CN
- China
- Prior art keywords
- bis
- formula
- pyrazine
- furans
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title abstract description 15
- 229940079593 drug Drugs 0.000 title abstract description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 24
- 238000003786 synthesis reaction Methods 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract description 11
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract description 11
- 239000013641 positive control Substances 0.000 abstract description 7
- 230000004083 survival effect Effects 0.000 abstract description 7
- 230000005779 cell damage Effects 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 5
- 230000004069 differentiation Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 230000006698 induction Effects 0.000 abstract description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 48
- 150000002240 furans Chemical class 0.000 description 30
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- 238000003756 stirring Methods 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 9
- 238000001914 filtration Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- IMCCZKHIPVEUEI-UHFFFAOYSA-N n,n-difluoroaniline Chemical class FN(F)C1=CC=CC=C1 IMCCZKHIPVEUEI-UHFFFAOYSA-N 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- UJZYHMZRXGNDFB-UHFFFAOYSA-N 1,3-benzothiazol-5-amine Chemical compound NC1=CC=C2SC=NC2=C1 UJZYHMZRXGNDFB-UHFFFAOYSA-N 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241001122767 Theaceae Species 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229910000474 mercury oxide Inorganic materials 0.000 description 3
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000021384 green leafy vegetables Nutrition 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 0 *c1cccc(Cl)c1 Chemical compound *c1cccc(Cl)c1 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- 102100027831 14-3-3 protein theta Human genes 0.000 description 1
- YEUFXMPHEYKKGP-UHFFFAOYSA-N 3-bromopyrazine-2-carbaldehyde Chemical compound BrC1=NC=CN=C1C=O YEUFXMPHEYKKGP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N c1nc2ccccc2[s]1 Chemical compound c1nc2ccccc2[s]1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- DADSZOFTIIETSV-UHFFFAOYSA-N n,n-dichloroaniline Chemical compound ClN(Cl)C1=CC=CC=C1 DADSZOFTIIETSV-UHFFFAOYSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 细胞存活率 |
空白对照组 | 100 |
模型组 | 22 |
阳性对照组 | 72 |
Ⅰa | 80 |
Ⅰb | 95 |
Ⅰc | 83 |
Ⅰd | 93 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710444718.3A CN107184584B (zh) | 2017-06-13 | 2017-06-13 | 一种治疗阿尔茨海默病的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710444718.3A CN107184584B (zh) | 2017-06-13 | 2017-06-13 | 一种治疗阿尔茨海默病的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107184584A CN107184584A (zh) | 2017-09-22 |
CN107184584B true CN107184584B (zh) | 2018-07-13 |
Family
ID=59879639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710444718.3A Expired - Fee Related CN107184584B (zh) | 2017-06-13 | 2017-06-13 | 一种治疗阿尔茨海默病的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107184584B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009037247A1 (en) * | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
CN105102454A (zh) * | 2013-03-29 | 2015-11-25 | 东亚St株式会社 | 作为cetp抑制剂的新型噁唑烷酮衍生物、其制备方法和包含其的药物组合物 |
WO2016080361A1 (ja) * | 2014-11-17 | 2016-05-26 | 日本新薬株式会社 | 経口投与用医薬組成物 |
-
2017
- 2017-06-13 CN CN201710444718.3A patent/CN107184584B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009037247A1 (en) * | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
CN105102454A (zh) * | 2013-03-29 | 2015-11-25 | 东亚St株式会社 | 作为cetp抑制剂的新型噁唑烷酮衍生物、其制备方法和包含其的药物组合物 |
WO2016080361A1 (ja) * | 2014-11-17 | 2016-05-26 | 日本新薬株式会社 | 経口投与用医薬組成物 |
Non-Patent Citations (2)
Title |
---|
High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation;Alex Crowe等;《Biochemical and Biophysical Research Communications》;20070319;第358卷;第1-6页 * |
阿尔茨海默病中Tau蛋白聚集抑制剂的研究进展;姚君亮 等;《应用化工》;20110930;第40卷(第9期);第1657-1663页,第1668页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107184584A (zh) | 2017-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111559991B (zh) | 一种萘胺类化合物及其盐的制备方法和应用 | |
CN108358973A (zh) | 萘酰亚胺四价铂类化合物、制备方法及其在制备抗肿瘤药物中的应用 | |
CN103735728A (zh) | 地骨皮醇提物、地骨皮甲素及乙素具有神经保护的新用途 | |
CN107556361A (zh) | 裂环羽扇豆烷衍生物及其抗肿瘤用途 | |
WO2012162912A1 (zh) | 苯并噻嗪硫酮衍生物及其制备方法和用途 | |
CN115417910A (zh) | 一种基于雷公藤红素靶向降解hsp90蛋白的化合物及其制备方法与应用 | |
CN109294980A (zh) | 红景天及红景天苷在干细胞定向分化为心肌样细胞中的应用 | |
CN108929329A (zh) | 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物 | |
CN116925054B (zh) | 紫丁香中的一种木脂素化合物及其制备方法与应用 | |
CN107184584B (zh) | 一种治疗阿尔茨海默病的药物 | |
CN104603133B (zh) | 用于治疗癌症和免疫抑制的组合疗法 | |
CN104829696A (zh) | 开环茜草科类型环肽,以其为活性成分的药物组合物,其制备方法和应用 | |
CN105085308B (zh) | 菖蒲酰胺类化合物及其制备方法与应用 | |
CN106831574A (zh) | N‑(1,2,3,4‑四氢异喹啉基)‑阿魏酰胺‑o‑烷基胺类化合物和应用 | |
CN107311988B (zh) | 一种治疗阿尔茨海默病的药物 | |
CN105384717B (zh) | 甘松新酮类化合物及其制备方法与应用 | |
CN106146395A (zh) | 3-羟基吡啶化合物、其制备方法及其制药用途 | |
CN110590779B (zh) | 3,10二对氯苯基6,12二氮杂四高立方烷类化合物及其合成方法、应用和药物组合物 | |
CN104224796B (zh) | 齐墩果烷型三萜类酯衍生物抗神经退行性药物用途 | |
CN104193808B (zh) | 茜草科类型环肽制备方法及其用作为Hippo-YAP信号通路抑制剂 | |
CN107573322A (zh) | 伊马替尼双氮氧化物、其制备方法和用途 | |
CN105399708A (zh) | 抗肝纤维化青霉呋喃酮a化合物及其药物组合物和应用 | |
CN109438339A (zh) | Rbp2酶抑制剂小分子化合物wxsa-072a及其制备方法与抗胃癌应用 | |
Li et al. | Design, Synthesis, and Neuroprotective Effects of Novel Cinnamamide-Piperidine and Piperazine Derivatives | |
CN103788058B (zh) | 一种木脂素类化合物及其在防治阿尔茨海默症中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhao Lei Inventor after: Zhao Fengqing Inventor after: Li Faqun Inventor before: Ju Defeng |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180522 Address after: 262500 4138 Linglong South Road, Qingzhou City, Weifang, Shandong province (Weifang Yi Du Central Hospital) Applicant after: Zhao Lei Address before: 262612 Wolong Town, Linqu County, Weifang, Shandong Applicant before: Ju Defeng |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180713 Termination date: 20210613 |
|
CF01 | Termination of patent right due to non-payment of annual fee |